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ABSTRACT 
Vaccination of neonates with Mycobacterium bovis bacillus Calmette-Guerin (BCG) 
may be a strategy that overcomes reduced vaccine efficacy associated with exposure 
to environmental mycobacteria in humans and cattle. Preliminary comparisons 
indicated that 2-week-old calves produced an immune response to vaccination at 
least as intense as that observed in adults. Subsequently, five gnotobiotic 
hysterotomy derived calves aged 1 day were inoculated with BCG and 3 months later 
were challenged intranasally with virulent M. bovis. The number of tissues with 
lesions and the pathological extent of these lesions was reduced significantly in 
vaccinates. Furthermore, lesions were evident in the lung or associated chest lymph 
nodes of four of five controls but none of five vaccinates. BCG vaccination reduced 
significantly the level of bacterial colonization. However, lesions in the head 
associated lymph nodes were observed in three of five BCG-vaccinated cattle. Levels 
of interferon gamma (IFN-gamma) detected by enzyme-linked immunosorbent assay 
(ELISA) or enzyme-linked immunospot (ELISPOT) in individual vaccinated animals 
at challenge did not correlate with subsequent resistance and in general immune 
responses post-challenge were lower in vaccinated calves. Low IL-10 responses were 
evident but IL-4 was not detected. Responses to ESAT-6 and/or CFP-10 were evident 
in four of four control calves that had lesions. Two of the BCG vaccinates with lesions 
did not produce a response to ESAT-6 and CFP-10, indicating that these antigens did 
not distinguish vaccinated immune animals from vaccinated animals with lesions. 
Overall, vaccination of neonatal calves with BCG induced significant protection 
against disease and has potential as a strategy for the reduction of the incidence of 
bovine tuberculosis. 
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Introduction 
In many countries the persistence or increased incidence of bovine tuberculosis (TB) 
poses a human health risk and a major economic problem. Bacillus Calmette–Guérin 
(BCG) was developed as a human tuberculosis vaccine in the 1920s, but despite its 
widespread use has a variable efficacy against pulmonary TB, ranging from 0% to 
80%[1,2]. Meta-analysis of human BCG trials revealed that BCG vaccination was 
most successful when administered during childhood and that this induced 
protection against meningeal and miliary TB more effectively than against 
pulmonary TB [2]. 
A number of hypotheses exist for the variable efficacy of BCG vaccination. One is 
interference or masking of protection by previous exposure to environmental 
mycobacteria [2]. Previous exposure may reduce the immunity induced by BCG 
vaccination, effective vaccine ‘take’ may be prevented [3], or previous exposure could 
prime an inappropriate bias in the immune response. On the other hand, there is 
evidence that exposure to environmental mycobacteria may give a low level of 
protection against Mycobacterium tuberculosis that cannot be improved upon by 
vaccination with BCG [4]. 
The highest prevalence of human TB is in Africa, Asia and Central America, where 
there is also a high incidence of exposure to environmental mycobacteria. Studies in 
Malawi indicated that pre-existing responses to mycobacterial antigens [purified 
protein derivative (PPD)] was associated with reduced interferon (IFN)-γ responses 
post-BCG vaccination in adults [5,6]. In contrast, vaccination of infants at birth in 
The Gambia was shown to induce strong IFN-γ responses in the absence of 
interleukin (IL)-4 [7,8]. These neonates had no pre-existing IFN-γ or IL-4 responses 
to PPD. However, infants studied at 4 months of age had considerable pre-existing 
IL-4 responses to mycobacterial antigen and less IFN-γ secretion was observed post-
vaccination. These data indicate the importance of early vaccination for strong Th1-
biased immunity. 
TB in cattle has a similar pathogenesis to that in humans and the kinetics of immune 
responses post-vaccination and post-virulent challenge can be measured easily [9]. 
Cattle, like humans and unlike mice, are immunocompetent at birth. In addition, 
cattle studies have also revealed variable efficacy of BCG vaccination [10–12]. Calves 
are usually sensitized to mycobacterial antigens early after birth and conventionally 
reared calves show responses to PPD by 6 weeks of age. Vaccination of adult cattle 
with pre-existing responses to environmental mycobacteria was much less effective 
than seen in animals without pre-existing responses [12]. 
Previously, we have demonstrated that BCG vaccination of 1-day-old gnotobiotic, 
germ-free calves provoked a strong PPD-B specific immune response [13,14]. Studies 
using conventionally reared neonatal cattle indicated that BCG vaccination within 8 
h of birth can provide very efficient protection against intratracheal/endobronchial 
challenge with virulent M. bovis[15]. However, a major constraint to the use of BCG 
as a vaccine in cattle is that it interferes with detection of TB by current skin and 
IFN-γ tests, and diagnostic tests utilizing M. bovis-specific antigens are being 
developed [16–20]. 
In a preliminary experiment we compared the response of neonatal and adult cattle 
to vaccination with BCG. The neonates responded more effectively than the adults, as 
judged by IFN-γ production by lymphocytes cultured with PPD (unpublished 
observations). If reduced responses to BCG vaccination result from environmental 
exposure it is proposed that neonatal vaccination could avoid this by priming for an 
appropriate response. The focus of this study was to investigate the protective 
efficacy of BCG vaccine when administered to neonatal calves. However, such studies 
provide valuable opportunities to test potential diagnostic antigens that may be 
useful in distinguishing vaccinated from infected cattle. This has been tested in a 
model in which calves were challenged intranasally, and the ability of the M. bovis-
specific antigens ESAT-6 and CFP-10 assessed for ability to detect vaccinated but 
challenged and diseased animals. 
 
MATERIALS AND METHODS 
Bacteria 
BCG Pasteur was diluted from previously titrated frozen (−70°C) stock grown in 
Middlebrook 7H9 broth containing 10% ADC supplement [21]. Numbers of colony-
forming units (CFU) were determined on 7H10 agar plates. M. bovis strain AF 
2122/97 [22] grown in 7H9 broth for 7 days was frozen at − 70°C. This strain was 
isolated in 1997 from a typical case of bovine TB in the United Kingdom and is a 
common spoligotype. It has been shown previously to be pathogenic to cattle by 
intratracheal instillation. A 1-ml aliquot was thawed and cultured in 10 ml of 7H9 
broth for 7 days at 37°C to produce log phase cells. The OD600 was measured and 
the culture was diluted in 7H9 broth to give an estimated 5 × 103 CFU per ml based 
on a comparison with a previously established standard curve. The number of CFU 
was determined on 7H11 agar containing 10% OADC supplement and 4·16 g pyruvate 
per litre. 
 
 
Animals and experimental plan 
British Holstein–Friesian calves (Bos taurus) were produced from cows inseminated 
with semen from major histocompatibility complex (MHC) homozygous bulls. One 
bull was A18/A18, the other A31/A31. All animals were bred at the Institute for 
Animal Health [23]. 
Two groups of five gnotobiotic calves derived by hysterotomy into plastic isolators 
[24] were inoculated subcutaneously with 106 CFU BCG or 7H9 medium at 1 day of 
age. Calves were transferred from the isolator into a high security unit when 
approximately 4 weeks of age, as dictated by UK animal welfare regulations, 
challenged intranasally with 1·3 × 104 virulent M. bovis when aged 12 weeks and 
necropsied 16 weeks later. 
The experiments were approved by the local ethics committee according to national 
UK guidelines. 
 
Post-mortem examination and bacteriology 
Lymph nodes of the head (retropharyngeal, submandibular, parotid) and thorax 
(mediastinal and four bronchus-associated), tonsils, nasal and tracheal mucosa and 
the seven pulmonary lobes were examined for gross lesions following the cutting of 
0·5–1 cm slices. Macroscopic lesions were scored as described previously [25]. 
Briefly, lymph nodes were assigned a score of 0 for no visible lesions, 1 for one to two 
small foci, 1–2 mm in diameter, 2 for several small foci 1–2 mm in diameter or a 
necrotic area 5 by 5 mm, 3 for multiple lesions or extensive necrotic areas and 4 for 
gross lesions extending over much of the lymph node. Lungs were assigned a value of 
0 for no visible lesions, 1 for no gross lesions but lesions apparent on slicing, 2 for up 
to 5 lesions <10 mm diameter, 3 for more than six lesions <10 mm in diameter, 4 for 
one distinct lesion >10 mm in diameter and 5 for gross coalescing lesions. Tissues 
were fixed in 10% formal saline and processed for histological examination following 
staining with haematoxylin and eosin (H&E). Tissues with typical lesions of TB 
evident by microscopy, but no gross lesions, were given a score of 1 in the overall 
pathology comparison. 
Tissue samples were frozen at − 70°C for subsequent bacteriological examination by 
titration of tissue homogenates on modified 7H11 agar [26]. 
 
Antigens 
Purified protein derivatives from M. avium (PPD-A) and M. bovis (PPD-B) were 
obtained from the tuberculin production unit at Veterinary Laboratories Agency 
(VLA), Weybridge, UK. Recombinant ESAT-6 and CFP-10 were as described [17]. 
Tuberculin skin tests 
 
The single comparative intradermal tuberculin test with avian and mammalian PPD 
(PPD-A and PPD-B, respectively) was by intradermal inoculation of 0·1 ml of PPD-A 
and PPD-B and reactions read 72 h later. Results were recorded as increase in skin 
thickness at 72 h compared to thickness pre-injection and interpreted according to 
the standard protocol (European Communities Commission regulation number 
1226/2002) [27]. 
 
Immunological assays 
Blood was collected into heparin (10 U/ml). For cytokine assays 4 ml of blood was 
incubated at 37°C for 24 h with PPD-A, PPD-B (final concentration of 20 µg per ml) 
diluted in RPMI + 50 µg/ml gentamicin. ESAT-6 and CFP-10 were used at a final 
concentration of 5 µg/ml. An equal volume of RPMI + gentamicin was used as 
control. The supernatant was removed after centrifugation and stored at − 20°C until 
assayed. IFN-γ (pg) and IL-10 (units) were assayed by enzyme-linked 
immunosorbent assay (ELISA) as described using recombinant bovine standards 
[28]. Each sample assayed was measured in duplicate by ELISA; the variability 
between samples was less than 5%. 
Secretion of IFN-γ by peripheral blood mononuclear cells (PBMC) was also assessed 
by enzyme-linked immunospot (ELISPOT) [29] with spots developed by the addition 
of 3-amino-9-ethylcarbazole (AEC) substrate (Kem-En-Tec Diagnostics) for 5 min, 
counted using the AID ELISPOT version 2.5 reader and software (Autoimmune 
Diagnostika, Strassberg, Germany) and are expressed as spot-forming cells (SFC) per 
106 PBMC. The maximum number of SFC that can be read accurately is 
approximately 2000 per 106 PBMC. 
An IL-4 ELISPOT assay was performed in a similar manner using MoAb CC313 and 
CC314-biotin (both produced at IAH) and shown to be effective in detecting natural 
IL-4 production in PBMC incubated with Con-A at 5 µg per ml (J. C. Hope, 
unpublished data). 
 
 
Statistical analyses 
Analyses were performed using MINITAB release 12·21. Differences in immunological 
responses, degree of pathology and bacterial colonization between BCG-vaccinated 
and control calves were compared using the Mann–Whitney U-test. Correlations 
between immune responses, bacterial burden and the degree of pathology were 
assessed non-parametrically using Spearman's rank correlation. 
 
RESULTS 
BCG vaccination of neonatal calves induces protection against disease 
caused by M. bovis challenge 
One group of five 1-day-old gnotobiotic neonatal calves was vaccinated with BCG and 
another (control) group of five calves was inoculated with medium. Twelve weeks 
later both groups of calves were challenged intranasally with 104 M. bovis. The 
protective efficacy of BCG vaccination against disease was assessed by post-mortem 
examinations performed 16 weeks post-challenge (Table 1). None of the animals 
showed clinical signs of disease. However, lesions typical of TB were observed in four 
of five non-vaccinated control animals and in three of five BCG-vaccinated calves. In 
the BCG-vaccinated group the lesions were confined to head lymph nodes, whereas 
in four of five non-vaccinated calves lesions were evident in the lung or in the lung 
associated lymph nodes. The extent of lesions varied considerably between animals, 
reflected by the lesion scores (Table 1). However, both the number of tissues affected 
and the lesion scores of the BCG-vaccinated group were significantly lower than the 
control group, indicating that BCG had conferred a degree of protection against M. 
bovis challenge (P < 0·05). 
BCG vaccination of neonatal calves reduces the level of bacterial 
colonization 
Bacteriological examination of tissues indicated that M. bovis was present in 
numbers up to 5 × 104 CFU/g from the majority of tissues with gross lesions (20/30 
tissues) but not from tissues with no lesions (3/90 tissues; Table 2), with a 
significant correlation between the number of isolated bacteria and lesion score (P < 
0·01). Fewer bacteria were present in tissues from the BCG-vaccinated group 
compared to the control group (P < 0·05) and significantly fewer tissues contained 
bacteria (P < 0·05). 
 
Skin test reactivity in BCG-vaccinated and control calves following M. 
bovischallenge 
Reactions to PPD in the skin test were observed in all animals 16 weeks after 
challenge with M. bovis (Table 3). Visible local clinical signs and increases in 
comparative skin thickness (PPD-B minus PPD-A) ranging from 3 to 31 mm were 
observed. Four of the five animals in each group would be classified as reactors, and 
one animal in each group inconclusive (animals no. 50 and no. 55), according to the 
standard interpretation of the tuberculin skin test. Using the severe interpretation of 
the test all 10 animals would be classified as M. bovis reactors. There appeared to be 
a trend indicating that BCG-vaccinated animals had lower skin test reactions 
compared to the non-vaccinated animals (7·2 ± 2·9 compared to 13·6 ± 10·2), but 
these were not significant (P = 0·156). 
 
Immunological responses in BCG-vaccinated versus control cattle 
Responses post-BCG vaccination 
Immune responses were monitored for 12 weeks in calves vaccinated with BCG (Fig. 
1a) and non-vaccinated animals (Fig. 1b). Significant increases in IFN-γ secretion in 
response to PPD were evident 2 weeks post-vaccination (P < 0·05). The peak IFN-γ 
response to BCG was detected between 2 and 4 weeks post-vaccination and this had 
waned significantly by week 12. There was no significant correlation between the 
overall IFN-γ produced during the 12-week vaccination period and the extent of 
protection against disease as assessed by lesion score (R2 = 0·046). Although small 
responses to PPD were noted at some time-points in the control group (Fig. 1b), 
these were not increased significantly above the response seen with medium. No 
significant difference in IL-10 secretion was detected between BCG-vaccinated and 
control calves (data not shown). 
 
Responses post-challenge 
Twelve weeks post-BCG vaccination both groups of calves were challenged with M. 
bovis. Lymphocytes from both groups of calves secreted IFN-γ post-challenge (Fig. 
1c,d). In the non-vaccinated group (Fig. 1d), IFN-γ secretion was observed by 3 
weeks. At 4 weeks post-challenge there was significantly more IFN-γ secreted in 
response to PPD compared to the vaccinated group (Fig. 1c, P < 0·05), suggesting a 
more rapid response to challenge in the control calves. There were consistently 
higher levels of IFN-γ secreted by calves in the non-vaccinated group (Fig. 1d) 
compared to the vaccinated group, but these differences were significant only at week 
4. Each of the calves in the control group showed different reactivity to ESAT-6 and 
CFP-10 (Fig. 2). Thus, calf no. 50 (Fig. 2a) did not respond to either antigen. ESAT-6 
responses were observed in calves nos 54 (Fig. 2b), 57 (Fig. 2c) and 59 (Fig. 2e) but 
not in calf no. 58 (Fig. 2d), which responded only transiently to CFP-10. Responses 
in the vaccinated group to these antigens were absent or very low and intermittent 
(<200 pg/ml at any time). 
Analysis of PPD-specific IFN-γ SFC by ELISPOT (Fig. 3) highlighted differences in 
the duration and magnitude of the IFN-γ response. There were more IFN-γ SFC in 
the non-vaccinated group than the BCG-vaccinated group and the responses were 
maintained for longer in the non-vaccinated calves. Thus, animals nos 54 (Fig. 3b), 
57 (Fig. 3c) and 59 (Fig. 3e) showed high numbers of IFN-γ SFC throughout the 16-
week challenge period, whereas responses in the BCG vaccinates nos 53 (Fig. 3g), 56 
(Fig. 3i) and 60 (Fig. 3j) had waned significantly by 16 weeks. Interestingly, no. 50 
(Fig. 3a), which had no visible lesions at post mortem, showed a positive ELISPOT 
response, suggesting a possible increased sensitivity of this assay for detection of 
infection. 
IL-10 was produced in both the control and BCG-vaccinated groups; however, no 
significant differences were observed (data not shown). No IL-4 responses were 
detected using PPD as antigen. 
 
Discussion 
Studies of cattle vaccinated with BCG, as with humans, have shown variable 
efficacies. This variability has been attributed to sensitization by environmental 
mycobacteria [12,30,31]. Thus, the hypothesis that vaccination prior to exposure to 
environmental mycobacteria might provide an enhanced level of protection obtained 
following BCG vaccination is worth thorough examination. 
This study is the first to demonstrate the efficacy of BCG against M. bovis infection 
by the intranasal route. Vaccination significantly reduced the number of diseased 
tissues, the extent of tuberculous lesions and bacterial colonization. Bacterial spread 
to the lung and associated lymphoid tissue was limited in this model but was also 
reduced by vaccination. It is generally accepted that an effective vaccine should 
provide protection against disease, but would also have an efficacious effect by 
reducing or abrogating the transmission of infection. Our observations suggest that 
BCG vaccination of neonates may not only reduce disease, but may also have an 
impact on cattle-to-cattle transmission of infection. 
The distribution of lesions induced by intratracheal/endobronchial instillation of M. 
bovis is similar to that observed in approximately 60% of animals that have been 
naturally infected with M. bovis. In these cases lesions are confined mainly to the 
lung and lymph nodes associated with the thoracic cavity [32–34]. Experimental 
infection with M. bovis via the intranasal route induces disease that involves the 
lymph nodes of the head and, to a lesser extent, those in the thoracic cavity and lung. 
This distribution of lesions is also evident in naturally infected cattle [32–35]. Recent 
studies employing an intratracheal/endobronchial challenge route have shown a 
significant level of protection of young cattle against M. bovis challenge. 
Vordermeier et al. demonstrated approximately 70% protection of 6-month-old 
calves following BCG vaccination [25]. Similar results were reported recently by 
Buddle et al. in calves vaccinated with BCG within 8 h of birth [15]. The intranasal 
challenge route has been used to produce disease in cattle and to produce cattle that 
transmit disease experimentally ([36] and unpublished). Vaccination linked to an 
intranasal challenge route provides an alternative model for assessing vaccine 
efficacy and related immune responses. The spread of M. bovis between cattle is 
thought to be via the respiratory route through nasal secretions or the generation of 
aerosols within the upper respiratory tract [35], and is associated with the presence 
of lesions with lymph nodes of the head [36,37]. Thus, we suggest that a strategy to 
limit bacterial colonization in the head-associated lymph nodes could reduce the 
excretion of bacteria and consequent cattle to cattle transmission of disease. 
Vaccination of 1-day-old calves induced strong IFN-γ responses to PPD-B evident 
within 1 week and peaking 2–4 weeks following vaccination, similar to other studies 
[15,20,38]. No correlation was found between the level of IFN-γ induced by BCG and 
the degree of protection; rather, high levels of IFN-γ are related to more extensive 
lesions [11,25]. Thus, the response to PPD-B was more rapid and significantly higher 
in the non-vaccinated group and was maintained at a high level for the entire post-
challenge study period. Reduced bacterial replication in vaccinated calves is probably 
the explanation for the differences in kinetics and intensity of the IFN-γ response. 
There was a significant correlation between lesion score and PPD-B-induced IFN-γ, 
as reported previously [39]. In the vaccinated calves, the response of PBMC to PPD 
detected by IFN-γ ELISPOT had waned by week 16 post-challenge, whereas in the 
control calves the response was maintained at a much higher level throughout the 
study period. The number of PPD-B-specific IFN-γ SFC could be correlated with 
lesion scores (R2 = 0·64). Thus, the two BCG-vaccinated animals with no visible 
lesions showed the lowest number of SFC. Conversely, the non-vaccinated and 
lesioned animals showed high numbers of IFN-γ SFC. The response pattern observed 
in vaccinated animals nos 53 and 56, where IFN-γ increases rapidly following 
challenge but is then reduced as the infection is controlled, is a useful correlate of 
protection in experimental studies of bovine TB [38,40] and points to a way in which 
the level of response in ELISPOT assays in vaccinated animals may be used to 
distinguish vaccinated immune from vaccinated animals with disease. 
What is required for cattle is a diagnostic test that not only identifies infected 
individuals and distinguishes them from vaccinates, but that also identifies 
individuals that are vaccinated but subsequently become infected and diseased. The 
ability to distinguish vaccinated and infected from vaccinated and immune animals 
needs to be on an individual animal basis, not just significant on a group or herd 
basis. This is necessary to identify accurately infected animals that are present in 
herds in low numbers and which may be a continuing source of infection. Differential 
diagnosis of BCG-vaccinated from M. bovis-infected cattle could be achieved using 
specific defined antigens that are present in virulent M. bovis but absent from BCG. 
These antigens include ESAT-6 and CFP-10 [41]. Approximately 70% of M. bovis-
infected cattle were detected using a combination of ESAT-6 and CFP-10 [25,42], 
and reactivity to a cocktail of ESAT-6 and CFP-10 correlated with disease severity 
was useful for differential diagnosis of BCG vaccinated and M. bovis-infected cattle 
and could also distinguish between those cattle vaccinated with BCG that were 
protected from M. bovis challenge by the endobronchial route from those that were 
not [20,25,43]. The percentage of calves that reacted to ESAT-6 and/or CFP-10 in the 
current study is consistent with published observations, but it would appear that 
there are specific antigens other than ESAT-6 and CFP-10 present in PPD-B that 
remain to be identified and would be useful for diagnosis of infection. None of the 
BCG-vaccinated calves responded consistently to ESAT-6 or CFP-10 post-challenge. 
This includes both vaccinated and solidly immune calves and those that were 
vaccinated and diseased. 
In summary, we have shown that vaccination of neonatal calves with BCG 
significantly reduces disease and bacterial load following intranasal challenge 
with M. bovis. Furthermore, the observations indicate that the specific antigens 
employed here will not necessarily distinguish BCG vaccinates with lesions from 
those without. However, it appears that a combination of as-yet-unidentified 
antigens and methods to assess the intensity and/or duration of the immune 
response can be developed and established as assays for this purpose. 
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Figures 
Fig.1 
 
IFN-γ secretion post-BCG vaccination and post-M. bovis challenge. Gnotobiotic 
calves were vaccinated at 1 day (a) of age with BCG. Control calves (b) were 
inoculated with medium. Responses were measured for 12 weeks. Subsequently, both 
BCG-vaccinated calves (c) and control calves (d) were challenged intranasally with 
M. bovis. Whole blood was stimulated with PPD-A (grey), PPD-B (black) or medium 
control (white) and IFN-γ secretion in supernatants was assessed by ELISA. Means ± 
s.d. for groups of five calves are shown. 
 
 
 
 
 
Fig.2 
 
 
Responses of calves to M. bovis specific antigens. Five non-vaccinated calves (a–e) 
were challenged intranasally with M. bovis. Whole blood IFN-γ responses to ESAT-6 
(black bars) and CFP-10 (grey bars) were assessed at the indicated times post-
challenge. Results for individual animals are shown: (a) no. 50, (b) no. 54, (c) no. 57, 
(d) no. 58, (e) no. 59. 
 
 
 
 
 
 
Fig.3 
 
Detection of post-challenge IFN-γ responses by ELISPOT. PBMC from control (a–e) 
and BCG-vaccinated (f–j) calves were isolated at the indicated time-points post-M. 
bovis challenge. The number of PPD-A (grey bars)- and PPD-B (black bars)-specific 
IFN-γ SFC was estimated by ELISPOT. The number of SFC obtained by stimulation 
with medium control was subtracted from the number of SFC observed following 
antigen stimulation. Results for individual animals are shown. 
 
Tables 
Tab.1  
Lesions at necropsy 16 weeks post M. bovis challenge in BCG-vaccinated and control 
calves. No lesions were evident in R and L tonsils, L and R diaphragmatic, L and R 
medial or intermediate lobes of the lung, or in three other bronchus associated 
lymph nodes. 
 
L and R = left and right. Twenty-two tissues were examined for each animal. Score 
0–4 indicates increasing severity of gross lesions. 
 
 
 
 
 
Tab.2 
M. bovis viable counts in tissues taken post mortem. 
 
aViable count (log10 CFU per g tissue). The limit of detection using the isolation 
technique is five colonies. No isolations were made from nasal mucosa, trachea, R 
and L apical lobes of lung apart from nasal mucosa of no. 59 (3.51 CFU per g). Twelve 
tissues examined for each animal. 
 
Tab.3 
Skin test responses 16 weeks post-challenge with M. bovis. 
 
a Increase in skin thickness from day 0 to day 3. 
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